☰
✕

North america europe and australia peanut allergy treatment market

North America, Europe, and Australia Peanut Allergy Treatment Market, by Drug Type (Epinephrine, Antihistamine, (Loratadine, Diphenhydramine, Others), Palforzia, Pipeline Drugs(Viaskin Peanut, Ligelizumab, CA002, PRT120, Dupilumab), by Route of Administration (Oral, Parenteral, Intranasal and Epicutaneous), by Distribution Channel, (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, and Australia) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Jun 2022
  • CMI5041
  • 370 Pages
  • Excel & Pdf
  • Pharmaceutical

Peanut allergies are an overreaction of the immune system to peanuts. A peanut allergy is one of the most common types of food allergies. Infants with eczema and/or egg allergy are more likely to develop a peanut allergy. Among all food allergies, peanut allergy is the most common, and individual with a peanut allergy are at a greater risk for anaphylaxis

The North America, Europe, and Australia Peanut Allergy Treatment Market is estimated to be valued at US$ 1,252.6 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).

Figure 1.North America, Europe, and Australia Peanut Allergy Treatment Market Share (%) in Terms of Value, By Drug Type, 2022

Increasing prevalence of peanut allergy is expected to drive market growth during the forecast period.

Increasing prevalence of peanut allergy is expected to drive growth of the North America, Europe, and Australia peanut allergy treatment market over the forecast period. For instance, According to a factsheet provided by Allergy UK, is a British medical charity dedicated to helping adults and children with their allergies, in July 2021, Peanut allergy affected around 2% of children in the UK. Peanuts are a common cause of food allergy. It usually develops in early childhood but, sometimes, peanut allergy can appear in adult age. Peanut allergy remains constant and only approximately 1 in 5 children outgrow their allergy by 10 years of age.

North America, Europe, and Australia Peanut Allergy Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,252.6 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 11.7% 2030 Value Projection: US$ 3,036.9 Mn
Geographies covered:
  • North America: U.S.,  Northeast,  Southwest,  West,  Southeast,  Midwest and Canada
  • Europe: U.K., Germany, France, Italy,  Spain,  Switzerland,  Netherlands,  Austria,  Czech & Slovakia, and Rest of Europe
  • Australia
Segments covered:
  • By Drug Type: Epinephrine, Antihistamine (Loratadine, Diphenhydramine, Others), Palforzia, Pipeline Drugs (Viaskin Peanut, Ligelizumab, CA002, PRT120, Dupilumab)
  • By Route of Administration: Oral, Parenteral, Intranasal, Epicutaneous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., Stallergenes Greer Ltd.
Growth Drivers:
  • Increasing Prevalence of Peanut Allergy
Restraints & Challenges:
  • High Cost of Peanut Allergy Drug

Figure 2.North America, Europe, and Australia Peanut Allergy Treatment Market Share (%), By Route of Administration, 2022.

Increasing product approvals for treatment of peanut allergy are expected to drive market growth during the forecast period.

Increasing product approvals for treatment of peanut allergy are expected to drive the North America, Europe, and Australia Peanut Allergy Treatment Market growth during the forecast period. For instance, In January 2020, Aimmune Therapeutics, Inc., a biopharmaceutical company engaged in developing and commercializing treatments for potentially life-threatening food allergies, announced that the U.S. Food and Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. Palforzia is the first approved treatment for patients with peanut allergy.

North America, Europe, and Australia Peanut Allergy Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Lockdown was imposed in several countries globally, which had a negative impact on the economy of the private healthcare sector globally. This lockdown resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. Thus, COVID-19 pandemic has affected the economy in three main ways: by directly affecting the production and demand, by creating disruptions in distribution channels, and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in North America, Asia Pacific, Europe, and other global regions had been disrupted due to lockdown. Moreover, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which were required to ensure safety in hospitals and provide treatment to patients with other diseases, which has also impacted the overall healthcare market negatively. One of the biggest challenges is regarding the supply of raw materials required for manufacturing drugs due to irregularities in the transportation system. Furthermore, due to the increasing number of patients suffering from COVID-19 and other life-threatening illnesses, product distributors are seeing erratic demand for products from retailers.

North America, Europe, and Australia Peanut Allergy Treatment Market: Restraint

The high cost of peanut allergy drug is expected to hinder the growth of North America, Europe, and Australia peanut allergy treatment market over the forecast period. Palforzia is the only treatment approved by the U.S. Food and Drug Administration for children in age group of 4 to 17 years, allergic to peanuts. In January 2020, the U.S. FDA approved palfori allergan powder to mitigate allergic reactions, including anaphylaxis, which may occur with accidental exposure to peanuts. Palforzia costs from US$ 2.77 to US$ 35.60 per unit, depending on the different dosages (Powder for oral administration supplied in 0.5 mg, 1 mg, 10 mg, 20 mg and 100 mg Capsules or 300 mg Sachets.). Monthly cost of palforzia is around US$ 890 and an annual price of Palforzia is approximately US$ 11,000 per year. Thus, the high cost of peanut allergy drug makes it unaffordable for patients and this unaffordability of drug by patients is expected to hamper the market growth.

Key Players

Key players operating in market the market include DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channels 
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Key developments
    • Pipeline Analysis
    • Collaborations and Agreements
    • Market Trends
    • Product Approval
    • Regulatory Scenario
    • PEST Analysis
    • PORTER’s Five Forces Analysis
    • Reimbursement Scenario
    • Prescriber Preference: Overview
    • Prescriber Overview
    • Treatment Algorithm
    • Epidemiology
  4. North America Europe and Australia Peanut Allergy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • Economic Impact
    • Impact on Peanut Allergy Treatment Market
    • COVID-19 Epidemiology
  5. North America Europe and Australia Peanut Allergy Treatment Market, By Drug Type, 2017-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Epinephrine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Antihistamine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
        • Loratadine
        • Diphenhydramine
        • Others
      • Palforzia
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
      • Pipeline Drugs
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
          • Viaskin Peanut
          • Ligelizuma
          • CA002
          • PRT120
          • Dupilumab
  6. North America Europe and Australia Peanut Allergy Treatment Market, By Route of Administration, 2017-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
    • Intranasal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
    • Epicutaneous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  7. North America Europe and Australia Peanut Allergy Treatment Market, By Distribution Channel, 2017-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  8. North America Europe and Australia Peanut Allergy Treatment Market, By Region, 2017-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
        • U.S.
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Sub-region, 2017-2030,(US$ Mn)
        • Northeast
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Southwest
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • West
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Southeast
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Southeast
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Midwest
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Canada
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
        • U.K.
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Germany
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • France
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Italy
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Spain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Switzerland
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Netherlands
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Austria
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Czech & Slovakia
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
        • Rest of Europe
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
          • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
    • Australia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • DBV Technologies*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Aimmune Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Prota Therapeutics Pty Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • COUR Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • BlueWillow Biologics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • HAL Allergy B.V
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allergy Therapeutics PLC
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Vedanta Biosciences, Inc
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Cambridge Allergy Ltd. (Camallergy)
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Angany Inc
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Moonlight Therapeutics Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Moonlight Therapeutics Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allero Therapeutics B.V.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sanofi
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Viatris Inc. (Mylan N.V.)
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Aurobindo Pharma Limited.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Siolta Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • DESENTUM OY
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • ALK
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Immunomic Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Stallergenes Greer Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
  10. Section
    • Research Methodology
    • About Us and Services
    • Contact

*Browse 75 market data tables and 39 figures on "North America Europe and Australia Peanut Allergy Treatment Market” - Forecast to 2030

Detailed Segmentation:

  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Drug Type :
    • Epinephrine
    • Antihistamine
      • Loratadine
      • Diphenhydramine
      • Others
    • Palforzia
    • Pipeline Drugs
      • Viaskin Peanut
      • Ligelizumab
      • CA002
      • PRT120
      • Dupilumab
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Route of Administration :
    • Oral
    • Parenteral
    • Intranasal
    • Epicutaneous
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Region:
    • North America
      • By Drug Type
        • Epinephrine
        • Antihistamine
          • Loratadine
          • Diphenhydramine
          • Others
        • Palforzia
        • Pipeline Drugs
          • Viaskin Peanut
          • Ligelizumab
          • CA002
          • PRT120
          • Dupilumab
      • By Route of Administration
        • Oral
        • Parenteral
        • Intranasal
        • Epicutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Northeast
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Southwest
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • West
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Southeast
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Midwest
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Canada
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Europe
      • By Drug Type
        • Epinephrine
        • Antihistamine
          • Loratadine
          • Diphenhydramine
          • Others
        • Palforzia
        • Pipeline Drugs
          • Viaskin Peanut
          • Ligelizumab
          • CA002
          • PRT120
          • Dupilumab
      • By Route of Administration
        • Oral
        • Parenteral
        • Intranasal
        • Epicutaneous
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.K.
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Germany
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • France
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Italy
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Spain
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Switzerland
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Netherlands
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Austria
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Czech & Slovakia
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Europe
          • By Drug Type
            • Epinephrine
            • Antihistamine
              • Loratadine
              • Diphenhydramine
              • Others
            • Palforzia
            • Pipeline Drugs
              • Viaskin Peanut
              • Ligelizumab
              • CA002
              • PRT120
              • Dupilumab
          • By Route of Administration
            • Oral
            • Parenteral
            • Intranasal
            • Epicutaneous
          • By Distribution Channel
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
      • Australia
        • By Drug Type
          • Epinephrine
          • Antihistamine
            • Loratadine
            • Diphenhydramine
            • Others
          • Palforzia
          • Pipeline Drugs
            • Viaskin Peanut
            • Ligelizumab
            • CA002
            • PRT120
            • Dupilumab
        • By Route of Administration
          • Oral
          • Parenteral
          • Intranasal
          • Epicutaneous
        • By Distribution Channel
          • Hospital Pharmacies
          • Retail Pharmacies
          • Online Pharmacies
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the North America, Europe, and Australia Peanut Allergy Treatment Market during the forecast period (2022-2030)?

The North America, Europe, and Australia Peanut Allergy Treatment Market size is estimated to be valued at US$ 1,252.6 million in 2022 and is expected to exhibit a CAGR of 11.7% between 2022 and 2030.

What are the major factors driving market growth?

Factor such as increasing prevalence of peanut allergy is expected to drive market growth over the forecast period.

Which is the leading drug type segment in the market?

Epinephrine segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include High cost of peanut allergy drug.

Which are the major players operating in the market?

Major players operating in the market are DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now